tiprankstipranks
Trending News
More News >
AdAlta Ltd. (AU:1AD)
ASX:1AD
Australian Market
Advertisement

AdAlta Ltd. (1AD) Price & Analysis

Compare
4 Followers

1AD Stock Chart & Stats


AdAlta Ltd. News

1AD FAQ

What was AdAlta Ltd.’s price range in the past 12 months?
AdAlta Ltd. lowest share price was AU$0.01 and its highest was AU$0.02 in the past 12 months.
    What is AdAlta Ltd.’s market cap?
    AdAlta Ltd.’s market cap is AU$5.29M.
      When is AdAlta Ltd.’s upcoming earnings report date?
      AdAlta Ltd.’s upcoming earnings report date is Mar 02, 2026 which is in 184 days.
        How were AdAlta Ltd.’s earnings last quarter?
        AdAlta Ltd. released its earnings results on Aug 26, 2025. The company reported -AU$0.003 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.003.
          Is AdAlta Ltd. overvalued?
          According to Wall Street analysts AdAlta Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does AdAlta Ltd. pay dividends?
            AdAlta Ltd. does not currently pay dividends.
            What is AdAlta Ltd.’s EPS estimate?
            AdAlta Ltd.’s EPS estimate for its next earnings report is not yet available.
            How many shares outstanding does AdAlta Ltd. have?
            AdAlta Ltd. has 1,321,316,500 shares outstanding.
              What happened to AdAlta Ltd.’s price movement after its last earnings report?
              AdAlta Ltd. reported an EPS of -AU$0.003 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
                Which hedge fund is a major shareholder of AdAlta Ltd.?
                Currently, no hedge funds are holding shares in AU:1AD

                AdAlta Ltd. Stock Smart Score

                Company Description

                AdAlta Ltd.

                AdAlta Limited, a clinical stage biotechnology company, discovers and develops protein therapeutics in Australia. The company's lead i-body drug candidate includes AD-214, which is in Phase I clinical trials for the treatment of idiopathic pulmonary fibrosis and other fibrotic diseases. It has collaborative partnerships with GE Healthcare to discover i-bodies that bind to granzyme B; and Carina Biotech Pty Ltd. to develop CAR-T cell products against various solid tumor antigens. AdAlta Limited was incorporated in 2006 and is headquartered in Bundoora, Australia.

                AdAlta Ltd. (1AD) Earnings & Revenues

                Similar Stocks
                Company
                Price & Change
                Follow
                Vectus Biosystems Limited
                Regeneus Ltd.
                Anatara Lifesciences Ltd
                Bio-Gene Technology Ltd.
                Hexima Ltd

                Ownership Overview

                1.99%98.01%
                Mutual Funds
                ― Other Institutional Investors
                98.01% Public Companies and
                Individual Investors

                Options Prices

                Currently, No data available
                ---
                Popular Stocks
                What am I Missing?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis